The nuclear expression of both EGFR and HER3 have been correlated with worse disease prognosis in specific cancers [9]–[11], [13], [29], and nuclear EGFR has been shown to enhance resistance to various therapeutic agents [4], [5]. This evidence concerns the gene ERBB3 and cancer.